Last week, drugmaker Endo International released its results for the second quarter of the year. The healthcare company posted revenue of $569.1 million in the period, a decrease of 20 per cent compared to $714 million in the second quarter of 2021. The company also reported a loss of $1.89 billion in its second quarter. Despite the fall in revenue and significant loss, the numbers exceeded the expectations of analysts. After all, the company has been lumbering from crisis to crisis in recent years over its alleged role in fuelling the opioid crisis in the United States. The company has…

Want to continue reading?

Join today with an Annual membership and get full access to The Currency for just €200 (68c per day) or try monthly membership for just €5 for your first month.

Subscribe

Cancel at any time.

Are you already a member? .